Panelists:
Ebihara Takashi, PhD
Chief Operating Officer
GeneFrontier Corporation
Panelist
Ebihara Takashi, PhD
Ebihara Takashi has been the chief operating officer of GeneFrontier (GFC) since 2010, with a focus on advancing cell-free protein expression technologies, particularly the PURE system. He earned a PhD in cell-free protein synthesis from the Tokyo Institute of Technology in 2000 and played a key role in the establishment of GFC in 2003, leveraging his expertise in cell-free protein synthesis following experience in venture capital.
Galit Meshulam-Simon, PhD
Associate Director, Commercial Applications
Elegen
Panelist
Galit Meshulam-Simon, PhD
Galit Meshulam-Simon holds a PhD from the Technion-Israel Institute of Technology in biotechnology and heads the Commercial Applications team at Elegen. With more than 17 years of expertise leading R&D teams, Meshulam-Simon’s career spans various aspects of synthetic biology, protein engineering, infectious disease diagnostics, and AI-driven enzyme discovery, driving innovations and partnerships in synthetic biology, molecular diagnostics, and genetic medicine development.
- Time:
While transcription-translation (TXTL) systems are powerful tools for screening recombinant proteins and antibodies, they frequently involve time-consuming bottlenecks during the synthesis of DNA templates. Although linear double-stranded DNA templates accelerate workflows, many commercial suppliers have struggled to provide the necessary length, complexity, or accuracy required to effectively replace plasmid- or PCR-based approaches. There is a need for more efficient and reliable DNA template solutions to fully leverage the advantages of TXTL systems in applications such as protein screening. Elegen’s ENFINIA
Linear DNA improves TXTL screening by successfully addressing several bottlenecks associated with traditional DNA template synthesis.
In this GEN webinar, our expert speakers will present a case study demonstrating the exceptional properties and high-fidelity performance of ENFINIA Linear DNA as evaluated in GeneFrontier’s cell-free protein synthesis PUREfrex® system. These results showcase ENFINIA’s outperformance in terms of DNA purity, transcription efficiency, and robust protein expression for various constructs. Attendees will learn:
● How this powerful combination eliminates the need for cloning or PCR amplification, significantly streamlining TXTL workflows
● How to reduce hands-on time and enable higher-throughput protein screening for synthetic biology, protein engineering, and drug discovery applications
● How to apply ENFINIA Linear DNA for challenging sequences such as long repeats, GC-rich promoters, and homopolymers
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
Produced with support from:
The post Accelerated Protein Screening with ENFINIA Linear DNA and GeneFrontier’s Cell-Free PUREfrex appeared first on GEN – Genetic Engineering and Biotechnology News.
